熱門資訊> 正文
勇敢之心生物公司报告第二季度业绩
2026-09-09 04:04
- Braveheart Bio, Inc. press release (BRVE): Q2
- Cash and cash equivalents were $122.8 million as of June 30, 2026, compared to $89.2 million as of December 31, 2025.
- Net loss was $15.0 million, and net loss attributable to common stockholders, after a deemed dividend upon the issuance of Series A preferred stock, was $18.6 million or $2.51 net loss per share, basic and diluted, for the three months ended June 30, 2026, compared to a net loss of $0.4 million, or $0.14 net loss per share, basic and diluted, for the same period in 2025.
More on Braveheart Bio, Inc.
- Braveheart Bio Readies $300 Million IPO Plan
- Heart drug developer Braveheart Bio surges on public debut after upsized IPO
- Braveheart Bio, Attovia seek $275M and $182M in U.S. IPOs
- Historical earnings data for Braveheart Bio, Inc.
- Financial information for Braveheart Bio, Inc.
推薦文章
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
